Since the lipid modification of RAS proteins by a farnesyl isoprenoid is a key step for this association in this context, farnesyl transferase inhibitors (FTI) were developed and in particular two compounds (lonafarnib and tipifarnib) were tested in solid tumors with KRAS mutation in clinical trials, including CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.